Indoco swings to ₹65 Cr profit on ophthalmic-sale gain; core still in the red

Indoco Remedies posted a consolidated Q1 FY27 net profit of ₹65.4 Cr versus a ₹36.4 Cr loss a year ago, but the swing is optical: the entire profit comes from a ₹97.3 Cr exceptional gain on the completed slump sale of its Ophthalmic Division to Sunways (India). Strip the one-off out and the group was still loss-making, with a pre-exceptional loss before tax of ₹19.6 Cr — narrower than the ₹36.7 Cr year-ago loss, but not a genuine operating turnaround. On an adjusted basis this is a narrowing loss, not the +₹65 Cr print the headline shows. Revenue was the one solid number: consolidated operating income rose 6.3% YoY to ₹467.5 Cr (−1.7% QoQ off the seasonally stronger March quarter), and standalone EBITDA margin expanded sharply to 10.3% from 3.8% a year earlier — a real operational recovery that management attributed to the resilient domestic formulations business. The growth mix, however, inverted the last-call guidance. Management had guided to 'continued strong growth in international formulations' with domestic merely tracking the IPM; the actual print was the reverse — India net sales jumped 12.2% YoY to ₹311.8 Cr while outside-India revenue was essentially flat at ₹154.5 Cr. The margin-improvement pillar of guidance was met, but the international-growth pillar was not, and MD Aditi Panandikar's own commentary conceded international and API businesses made only 'steady progress.' Below EBITDA, high finance costs (₹28.3 Cr) and depreciation (₹34.5 Cr) still drag the group into a pre-exceptional loss, and the auditors flagged a going-concern uncertainty on US arm FPP Holding LLC (negative net worth ₹38.2 Cr). No Q1-specific street consensus exists for this small-cap; against the SMIFS FY27E EBITDA-margin bar of ~10.9%, the ~10.3% standalone print lands roughly in line. The Ophthalmic-sale proceeds set up the flagged ~₹140 Cr FY27 debt-reduction plan; the real test next quarter is whether the core can turn profitable without one-offs.